- a adjunct to anti-viral treatment;
- a therapy for non-responders to anti-viral (interferon) treatment;
- a therapy for HBV and HCV induced Acute and Chronic Viral Hepatitis;
- a therapy for any co-hosted combination of: HBV, HCV, HIV, Cirrhosis, and Liver Cancer;
- a prophylaxis therapy for HBV and HCV antiviral treatment to maximize the efficacy and minimize the adverse side effects of interferon and other antiviral drugs;
- a therapy to manage Liver Cirrhosis;
- a therapy where anti-viral treatment was declined due to exclusion criteria such as diabetic, drug, alcohol and other problems.
HBV/HCV - Chronic Viral Hepatitis
The Silent Killer" - a serious disorder caused by HBV and HCV that has a general tendency to progress to hepatic cirrhosis and possibly even primary liver cancer.
BioMonde's response!
The Global Burden of viral hepatitis HBV and HCV
The commonest chronic viral infections are associated with Hepatitis B (HBV) with 170 million people and Hepatitis C (HCV) with up to 300 chronically infected worldwide. Between 8,000 and 10,000 people die of hepatitis C and 5,000 people die of hepatitis B annually in the US.
Problems associated with anti-viral treatments for HBV and HCV
- Chronic active hepatitis;
- Non-response;
- High occurrence of relapse;
- Adverse side-effects;
- Badly tolerated;
- Limited beneficial effects;
- Not readily available;
- Expensive;
- Broad exclusion criteria;
- Inconvenient delivery methods.
FDA-approved (HBV) Treatments
-
Baraclude (entecavir)
EpivirHBV (lamivudine; 3TC)
Intron A (interferon alfa-2b)
Hepsera (adefovir dipivoxil)
Pegasys (peginterferon alfa-2a)
Tyzeka (telbivudine)
FDA-approved (HCV) Monotherapies
-
Intron A
Roferon
Infergen
Pegasys
PEG-Intron
FDA-approved (HCV) Combination Therapies
-
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Development of a optimized, safe, effective and affordable class
of novel anti-hepatoinflammatory (anti-hepatitis) and hepatoprotector umbelliferone
derivatives (4-meythylumbellierone).
Whilst anti-viral treatment targets the virus that causes Chronic Viral Hepatitis, BioMonde focuses on managing Chronic Viral Hepatitis.
Umbelliferone derivatives (4-meythylumbellierone) can greatly lessen liver inflammation, Hepatitis, and dramatically improve elevated liver enzymes, which are indications of Liver damage associated with Chronic Viral Hepatitis, HBV and HCV. By controlling liver inflammation and liver enzymes, it is possible to prevent and minimize liver scarring (fibrosis), and progression to cirrhosis and liver cancer, irrespective of viral loads.
Umbelliferone derivatives (4-meythylumbellierone) also stimulate liver function, including the regeneration tissue damage. Whilst is may not be possible to repair liver scarring (fibrosis) associated with cirrhosis, it is possible to slow its progression.
BioMonde derivatives are not only an ideal prophylaxis and adjunct to anti-viral treatment such as Interferon, they offer a viable and effective option for Interferon non-responders and many previously excluded from anti-viral treatment. Consequently, BioMonde's approach means that more HBV and HCV patients can have access to effective healthcare.
REFERENCE MATERIAL
Published, Peer Reviewed Studies and Medical Opinion click-here
View our product pipeline
click-here
Products containing umbelliferone derivatives
(4-Methylumbelliferone) click-here
HEPARVIT™ ProHEP
HBV Virus
HCV Virus
Medical research...........
Indicates that umbelliferone derivatives (4-meythylumbellierone) administered with or without anti-viral treatment greatly improves the underlying symptoms associated with Chronic Viral Hepatitis and the progression of HBV/HCV.
- diminishes liver inflammation (Hepatitis);
- lowers elevated liver enzymes;
- lessens abdominal pain;
- minimizes liver cell damage;
- stimulates cellular regeneration in the liver;
- decreases lethargy and fatigue associated with HBV, HCV, and anti-viral drugs;
- protects the liver against the toxic affects of drugs, alcohol, anabolic steroids, etc.;
- helps normalize liver function;
- improves the efficacy of anti-viral drugs by improving tolerance, reducing adverse side-effects and toxicity.